TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02559102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Description: Patients receive dexmedetomidine sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General sevoflurane anaesthesia
Description: Patients receive general sevoflurane anaesthesia with endotracheal intubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal anaesthesia
Description: single shot caudal anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal anaesthesia
Description: single shot caudal anaesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal hernia surgery
Description: Infant inguinal hernia repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia surgery
Description: Infant inguinal hernia repair.
Study: NCT04527640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg
Description: Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of synbiotics per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same synbiotics per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will undergo baseline examination including medical history and physical examination, blood samples will be collected for hemoglobin, WBC, platelet, urea, creatinine, albumin and indoxyl sulfate level. Patients will be asked to complete 2 questionnaires the PAC-SYM and PAC-QOL questionnaires, and will undergo food recall evaluations by a nutritionist. They will then be given 2 capsules of placebo per day for 30 days. After 1 month of intervention, the patients will be evaluated for food recall and side effects. Afterwards, the patients will receive 2 capsules of the same placebo per day for the next 30 days. After 2 months of intervention, the patients' history will be taken, they will be asked to complete the PAC-SYM and PAC-QOL questionnaires, undergo food recall examination, and side effects evaluation. Blood samples will be taken for indoxyl sulfate examination.
Study: NCT00426166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: 7500 megawatts with a 980 nm treatment beam every 48 hours for two weeks beginning at suture removal.
Study: NCT01071057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline/Morphine
Description: Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
Study: NCT01673529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB705498
Description: 1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match SB705498 will be used in both Part A and Part B of the study.
Study: NCT01343394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Umbilical Cord Blood
Description: 6 million cells/kg will be administered intravenously at one treatment time point.
Study: NCT03303326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate interview
Description: A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
Study: NCT02546232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy
Study: NCT02182323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Study: NCT03974048

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for DNA methylation analysis
Description: DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for DNA methylation analysis
Description: DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
Study: NCT03059316

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Massimo device
Description: Massimo is a newly introduced device which can measure the peripheral organ perfusion and expressed it as perfusion index(PI).

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Massimo device
Description: Massimo is a newly introduced device which can measure the peripheral organ perfusion and expressed it as perfusion index(PI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin drug
Description: Nitroglycerin is a drug used as an hypotensive agent through its vasodilation effect on veins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Labetalol is an antagonist of adrenergic receptors (a1, b1, b2) which is used as an hypotensive inducer. This drug targets the beta receptors 5 to 10 times more specific than alpha receptors so that minor tachycardia happens
Study: NCT03969914

Intervention type: PROCEDURE
Intervention: PEEP changes
Description: All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
Study: NCT03043534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shave gel
Description: Non marketed pre-shave gel with the following INCI list of ingredients:~WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brush
Description: All subjects randomized to brush will use the brush with each shave
Study: NCT00623402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 2x 400 mg orally per day (4 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon α-2b
Description: 3 µg/kg body weight s.c. once a week
Study: NCT03517033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Nebivolol Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forest Pharmaceuticals Inc.'s Bystolic Tablets
Study: NCT01850277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External electrical cardioversion (EEC)
Description: The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.~If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy to slow and control ventricular rate
Description: The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% \>95%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrioventricular junction ablation (AVJA)
Description: The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
Study: NCT02930031

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine
Description: 20 mg//kg/day, orally, daily for eight days following exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500 mL orally, daily for eight days following exercise
Study: NCT01657851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutasteride/tamsulosin
Description: Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
Study: NCT00585481

Intervention type: PROCEDURE
Intervention: Samples collection for viral diagnosis
Description: At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).~Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment.

Intervention type: PROCEDURE
Intervention: Lung Function Analysis
Description: Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
Study: NCT02102295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental toothpaste
Description: Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste
Description: Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
Study: NCT04456634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)
Description: Rux administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 20 mg/120 mg artemether-lumefantrine (AL) + Placebo
Description: Placebo administered 2 hours after AL administration, twice daily (b.i.d) for 3 consecutive days (6 doses in total).
Study: NCT00914186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS022
Description: Lotion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS022
Description: Lotion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS022
Description: Lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Lotion
Study: NCT04092686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 75mg
Description: SEP-363856 75mg tablet dosed once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856 100mg
Description: SEP-363856 100mg tablet dosed once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet dosed once daily
Study: NCT02309944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Wound Closure
Description: The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if \>2 cm deep, followed by staple or suture closure of the skin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Closure
Description: The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if \>2 cm deep, followed by staple or suture closure of the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena™ Incision Management System
Description: At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
Study: NCT01916135

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-SKI-249380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood will be drawn at the multiple time points for pharmacokinetic \& metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
Study: NCT03790111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telotristat ethyl
Description: XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) three times a day plus first line therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) three times a day plus first line therapy for the duration of the study
Study: NCT02326285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
Study: NCT00455299

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ventral hernia repair
Study: NCT01139814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amigo catheter robot
Description: The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
Study: NCT01145534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glibenclamide
Description: 5 mg as pills, taken daily during the morning for 60 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medicinal plant infusion
Description: INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
Study: NCT02529540

Intervention type: OTHER
Group type: OTHER
Intervention: Adjustable glasses
Description: The glasses will be used for refraction and wearing within professional instructions.

Intervention type: OTHER
Group type: OTHER
Intervention: Custom standard glasses
Description: The custom standard glasses are made by the traditional standards after refraction.

Intervention type: OTHER
Group type: OTHER
Intervention: Ready-made glasses
Description: The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
Study: NCT02962258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
Description: oral, crossover

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tribenzor of Daichi Sankyo Inc. USA
Description: oral, crossover
Study: NCT04785495

Intervention type: OTHER
Intervention: Quality-of-life assessment
Description: Patients will be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero (before the application of chemotherapy) and then after 6 day, after application of chemotherapy.
Study: NCT02620501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: topical lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.45% Normal Saline
Study: NCT03900494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VHC 1
Description: Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 1. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VHC 2
Description: Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 2. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
Study: NCT00433641

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sibutramine
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine
Description: oral 15 mg sibutramine once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sibutramine
Description: oral sibutramine 10 mg once per day
Study: NCT00432484

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lingzhi and Sen Miao San
Description: G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
Study: NCT02386020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aloe vera
Description: After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: After SRP, placebo gel was delivered subgingivally into periodontal pockets.